ConductScience.org, home

Paper36563

Cyclophosphamide therapy of severe systemic necrotizing vasculitis.

Fauci AS and 3 others. N Engl J Med, 1979. Cited by 538 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. Papers, record 36563. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36563

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cyclophosphamide therapy of severe systemic necrotizing vasculitis.
PubMed
Journal
N Engl J Med
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
538
iCite
Relative citation ratio, by iCite
25.2
iCite
Revised in PubMed
2013-11-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fauci ASA S
2Katz PP
3Haynes BFB F
4Wolff SMS M

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CyclophosphamideMajor topic
Polyarteritis NodosaMajor topic
VasculitisMajor topic
Adolescent
Adrenal Cortex Hormones
Adult
Azathioprine
Female
Humans
Male
Middle Aged
Necrosis
Recurrence
Remission, Spontaneous
Syndrome
Time Factors

Source PubMed

Download CSV of topics

Cited by84

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 538 citations.

PMIDTitleJournalYearIn PapersSource
42383040Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab.Front Med (Lausanne)2026https://conductscience.org/library/papers/42383040PubMed
41052893Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide.RMD Open2025https://conductscience.org/library/papers/41052893PubMed
40250881Myocardial infarction in ANCA-associated vasculitis: a population-based cohort study.RMD Open2025https://conductscience.org/library/papers/40250881PubMed
39969779The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium.Drugs2025https://conductscience.org/library/papers/39969779PubMed
39077977Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Diffuse Alveolar Hemorrhage With Avacopan.ACR Open Rheumatol2024https://conductscience.org/library/papers/39077977PubMed
39036255Rheumatoid Vasculitis in Modern Era: A Case Report and Comprehensive Literature Review.Cureus2024https://conductscience.org/library/papers/39036255PubMed
38913291Classification Criteria for ANCA Associated Vasculitis - Ready for Prime Time?Curr Rheumatol Rep2024https://conductscience.org/library/papers/38913291PubMed
38558645A Rare Presentation of Polyarteritis Nodosa (PAN).Cureus2024https://conductscience.org/library/papers/38558645PubMed
37979959Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.Ann Rheum Dis2024https://conductscience.org/library/papers/37979959PubMed
37947275ANCA-associated vasculitis-treatment standard.Nephrol Dial Transplant2024https://conductscience.org/library/papers/37947275PubMed
37547534Outcomes in ANCA-Associated Vasculitis in Scotland: Validation of the Renal Risk Score in a Complete National Cohort.Kidney Int Rep2023https://conductscience.org/library/papers/37547534PubMed
36505909Caecal Ameboma, colorectal malignancy mimicker in young male with ANCA-associated vasculitis.IDCases2023https://conductscience.org/library/papers/36505909PubMed
36244021Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.Clin Exp Med2023https://conductscience.org/library/papers/36244021PubMed
33909172Novel Therapies for ANCA-associated Vasculitis.Curr Rheumatol Rep2021https://conductscience.org/library/papers/33909172PubMed
33512781Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments.ACR Open Rheumatol2021https://conductscience.org/library/papers/33512781PubMed
33372616French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides).Orphanet J Rare Dis2020https://conductscience.org/library/papers/33372616PubMed
32833085Certain perspectives about the use of corticosteroids for managing hospitalized patients with rheumatic diseases.Clin Rheumatol2020https://conductscience.org/library/papers/32833085PubMed
31242923Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist.Pediatr Rheumatol Online J2019https://conductscience.org/library/papers/31242923PubMed
30413153Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study.BMC Nephrol2018https://conductscience.org/library/papers/30413153PubMed
29971584Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.Clin Rheumatol2018https://conductscience.org/library/papers/29971584PubMed

See all 84 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36563

GET https://conductscience.org/api/papers/v1/36563/cited_by?page=2